Introduction
Pete’s background as a fighter pilot informs his entire perspective on medical advocacy. He views the human body through a lens of performance and mission readiness, treating biological markers as “thresholds” that must be maintained to ensure operational success. His focus on “Ground Truth” data and systemic balance brings a rigorous, analytical mindset to the often-nebulous world of supplemental therapy.
The Vitamin D3 regimen originated in 2010 when Pete identified a correlation between sun exposure and the cessation of his cluster headache cycles. This led to the development of a structured protocol centered on a loading dose of 600,000 IU administered over six days. For those who do not respond to this initial phase, Pete notes that a second or even third loading schedule totaling 1.2 to 1.8 million IU may be necessary to reach a therapeutic level. Maintenance typically requires 7,000 to 10,000 IU per day to keep serum 25(OH)D3 levels above a critical threshold, which Pete identifies as 115 to 120 ng/mL for himself, though others may find relief at 100 ng/mL. A critical insight for 2025 is the superior efficiency of water-soluble delivery systems, such as Biotech D3-50; Pete found that 7,000 IU of water-soluble D3 maintained his levels more effectively than 10,000 IU of oil-based supplements.
The biological efficacy of this regimen is rooted in gene expression and the role of mRNA. Pete explains that Vitamin D3 acts as an instruction manual for the cell, utilizing messenger RNA to regulate the production of proteins. Specifically, the protocol seeks to downregulate inflammatory neuropeptides like CGRP, Substance P, and PACAP, which are the primary drivers of the “lightning strikes” of pain in cluster and migraine pathophysiology. To implement this safely, Pete mandates establishing “Ground Truth” through baseline laboratory tests for Vitamin D3, Calcium, and Parathyroid Hormone (PTH). While the “hypervitaminosis D” label is often used as a deterrent, Pete reports zero cases of hypercalcemia or kidney stones among thousands of followers over 15 years, provided they monitor these markers and maintain high hydration levels—at least two liters of water daily for those on high-dose therapy.
Data from Pete’s survey of over 313 participants indicates a 70 to 75 percent success rate once therapeutic serum levels are reached. For the remaining 25 percent of non-responders, the “Full Monty” of co-factors becomes essential. This includes Magnesium, Vitamin K2 (balancing MK7 and MK4 to direct calcium into the bones rather than soft tissue), and the synergistic pairing of Zinc and Quercetin. Pete describes Quercetin as a “soap bubble” that allows water-soluble Zinc to cross fatty cell membranes to inhibit viral replication and systemic inflammation. Recent studies, such as Lunde et al. (2025), support Pete’s long-standing assertion that systemic inflammation persists even outside of active headache cycles, justifying a permanent, high-level maintenance approach. By treating the body as a system in need of specific biological fuel, Pete has proven that for the treatment-refractory patient, there is indeed light at the end of the tunnel.
Want to know more about the Vitamin D3 Anti-Inflammatory Regimen for Cluster & Migraine Headache? The information is hosted for free over at www.vitamindregimen.com
